Bulletin
Investor Alert

press release

May 9, 2022, 7:31 a.m. EDT

Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

CAMBRIDGE, Mass., (BUSINESS WIRE) -- Syros Pharmaceuticals /zigman2/quotes/201168308/composite SYRS -3.96% , a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 4664097. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com . An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARa agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter ( @SyrosPharma ) and LinkedIn .

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005028/en/

SOURCE: Syros Pharmaceuticals

Media:
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
csolberg@syros.com Investor:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

COMTEX_406912617/2456/2022-05-09T07:30:32

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/201168308/composite
US : U.S.: Nasdaq
$ 0.97
-0.04 -3.96%
Volume: 522,059
Aug. 16, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$63.64 million
Rev. per Employee
$203,565
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.